

2016 NC Psychiatric Association Annual Meeting & Scientific Session

Major Depression: A Closer Look at Current & Emerging Treatments

September 8-11, 2016 | Asheville, NC

CME Meeting Mission Statement: Designed for psychiatrists, this continuing medical education live activity will provide information to maintain and expand competency and medical knowledge.

Credit Statement: The American Psychiatric Association designates this live activity for a maximum of 17.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Meeting Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint provider-ship of the American Psychiatric Association (APA) and the North Carolina Psychiatric Association. The APA is accredited by the ACCME to provide continuing medical education for physicians.

Disclosure Statement: The American Psychiatric Association requires disclosure by faculty at CME activities of any significant financial interest(s) or other affiliations(s) with commercial organization(s) that may have a director or in-direct interest in the subject matter of the educational activity. A “financial interest” may include, but is not limited to, being a shareholder in the organization, being on retainer with the organization, or having research or honoraria paid by the organization. An “affiliation” may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Acknowledgement of Commercial Support: Support for this program was provided by an unrestricted educational grant from PhRMA.

Conference Objectives: By the end of this program participants will be able to:

- Critically discuss and evaluate the evidence base for psychiatric practice
- Examine public policy trends and their potential impact on psychiatric practice
- Identify emerging clinical practices and their promise for implementation

Target Audience: This activity is intended for psychiatrist, psychologists, primary care physicians, nurse practitioners, nurses, physician assistants, social workers, and administrators.

JOINTLY PROVIDED BY THE AMERICAN PSYCHIATRIC ASSOCIATION (APA) AND THE NORTH CAROLINA PSYCHIATRIC ASSOCIATION.

Planning Committee: All Program Committee members agreed to disclose any conflict of interest that may arise during the planning of CME activities and recuse themselves from any discussions where a potential bias could exist.

Philip Ninan, M.D.: Consultant: Lundbeck

Michael Zarzar, M.D.: Stock: Glaxo Smith Kline, Lilly; Speakers Bureau: Lundbeck/Takeda

Thomas Penders, M.D., M.S.: Nothing to Disclose

Don Buckner, M.D.: Nothing to Disclose

Burt Johnson, M.D.: Nothing to Disclose

Brad Reddick, M.D.: Nothing to Disclose

Ranota Hall, M.D.: Nothing to Disclose

Jacqueline Smith M.D.: Nothing to Disclose

Stephen Kramer, M.D.: Consultant: DynaMed Plus

Chris Aiken, M.D.: Nothing to Disclose

Robin Huffman: Nothing to Disclose

Katy Kranze: Nothing to Disclose

Faculty

Larry Park, M.D.: Nothing to Disclose

Lori Raney M.D.: Nothing to Disclose

Samantha Melzer-Brody, M.D.: Grant/Research: NIH Foundation of Hope Sage Therapeutics Johnson and Johnson/Janssen

Sy Saeed, M.D.: Nothing to Disclose

Pierre Blier, M.D., PhD: Grant/Research: Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Forest, Euthymics, Janssen, Lundbeck, Merck, Otsuka, Pfizer, Pierre Fabre, Servier, Shire, Takeda, Valeant Helen Mayberg, M.D.: Consultant: St. Jude Medical

Stephen Wyatt, D.O.: Nothing to Disclose

Philip Ninan, M.D.: Consultant: Lundbeck

Eric Morse, M.D.: Speaker's Bureau: Indivior, BDSI, Orexo

Deanna Adkins, M.D.: Research Study with Otsuka

Echo Meyer, Ph.D.: Nothing to Disclose

Scott Leibowitz, M.D.: Nothing to Disclose

Michael Thase, M.D.: Stock: MedAvante Inc.; Consultant: Alkermes, Allergan, AstraZeneca, Bristol-Myers Squibb, Cercecor Inc., Eli Lilly, Forest Laboratories, Gerson Lehrman Group, Fabre-Kramer Pharmaceuticals Inc. GlaxoSmith-Kline, Guidepoint Global, Lundbeck, MedAvante Inc., Merck, Moksha8, Naurex, Inc., Neuronetics Inc., Novartis, Ortho-McNeil Pharmaceuticals, Otsuka, PamLab LLC, Pfizer, Shire US Inc, Sunovion Pharmaceuticals, Trius Therapeutic Inc, Takeda; Grant/Research: Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest Pharmaceuticals, Janssen, National Institute of Mental Health, Otsuka Pharmaceuticals; Royalties: American Psychiatric Foundation, Guildford Publications, Herald House, WW Norton & Co, Spouse Employment, Peloton Advantage